Curated CRC research, accessible, accurate, actionable

The CRC Digest

Tuesday, September 22, 2026

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

CRC Research Update

• ▸ TREATMENT

  Fruquintinib approved in U.S., EU, and China for previously treated metastatic CRC

  This oral VEGF receptor inhibitor demonstrated consistent efficacy in two Phase 3 trials: FRESCO (enrolling patients in China) and FRESCO-2 (enrolling patients across 14 countries in North America, Europe, Asia, and Australia), with patients receiving 5 mg once daily on a 3-weeks-on, 1-week-off schedule. (Clin Transl Sci)

• ◇ RESEARCH

  Gut bacterium Eggerthella lenta linked to liver metastasis via vascular barrier disruption

  Multi-omics analysis of two cohorts comprising 20 healthy controls, 82 non-metastatic CRC patients, and 65 patients with liver or lung metastases found that those with CRC liver metastasis had impaired gut vascular barrier function and bacterial colonization at metastatic sites, with E. lenta enriched in these patients. (Cell Discov)

• ◇ RESEARCH

  MSS colorectal cancer may not be universally immunotherapy-resistant

  A review in Trends in Cancer argues that resistance in proficient mismatch repair tumors is conditional, shaped by disease stage, metastatic anatomy, and spatial immune architecture rather than being uniformly "cold." (Trends Cancer)

• ▪ SCREENING

  Experts call for personalized screening based on individual risk factors beyond family history

  A review in Expert Review of Gastroenterology & Hepatology notes that while overall CRC incidence has declined, younger patients have experienced a rise, suggesting a more complex risk profile than current average-versus-high-risk guidelines capture. (Expert Rev Gastroenterol Hepatol)

Today's research spans approved therapies, microbiome mechanisms, and evolving approaches to screening and immunotherapy stratification.